Healthcare Industry News: sinusitis
News Release - June 25, 2007
Naryx Pharma, Inc. Announces the Appointment of Andy H. Strayer, Pharm.D. as Vice President of Clinical Operations and Medical AffairsSANTA BARBARA, Calif.--(HSMN NewsFeed)--Naryx Pharma, Inc., a leader in the development of new therapies for patients with chronic sinusitis, announced today that Andy H. Strayer, Pharm.D., has joined its management team as Vice President of Clinical Operations and Medical Affairs. Dr. Strayer will oversee the internal and external operations of our clinical development programs, including staffing, vendor management, and clinical trial logistics. Dr. Strayer will be located in Naryx's San Diego office.
Dr. Strayer joins Naryx from Pharmaceutical Product Development, Inc. (PPD), where he was Senior Vice President of Clinical Operations for the Americas and Asia. Dr. Strayer joined PPD in 1996 as Associate Director of the Antivirals and Anti-infectives Division. He progressed through several roles of increasing responsibility, including Executive Director of Clinical Operations for the West Coast and the Pacific Rim and Vice President of Clinical Operations for North America. Prior to joining PPD, Dr. Strayer was an Assistant Professor at the University of Kansas School of Pharmacy, and completed a Post-Doctoral Fellowship in Infectious Disease at the University of Rhode Island College of Pharmacy. He earned his B.S. and Pharm.D. degrees at the University of Kansas School of Pharmacy.
"We are very pleased that Andy is joining our management team," said Robin Campbell, Ph.D., President and Chief Executive Officer. "Andy has an outstanding track record of success in clinical development operations, and his experience and leadership will be instrumental to Naryx as we continue to grow as an organization dedicated to helping patients with chronic sinusitis."
About Naryx Pharma
Naryx(TM) is a privately-held company dedicated to developing innovative therapies for chronic sinusitis, based on advances in the targeted delivery of medications. Chronic sinusitis is a disease that afflicts up to 30 million people in the U.S. alone. The Company will focus on obtaining marketing approvals for its promising intellectual property portfolio of intranasal drug formulations. The company's lead product in development, Sybryx(TM), has received Fast-Track Designation from the FDA for the treatment of chronic sinusitis in patients who have undergone previous sinus surgical procedures.
Source: Naryx Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.